Details of Host Protein-DME Interaction (HOSPPI)
| General Information of Drug-Metabolizing Enzyme (DME ID: DME0411) | |||||
|---|---|---|---|---|---|
| DME Name | Microsomal cytochrome MCB5 (CYB5A), Homo sapiens | DME Info | |||
| UniProt ID | |||||
| EC Number | EC: 1.14.14.1 (Click to Show/Hide the Complete EC Tree) | ||||
| Lineage | Species: Homo sapiens (Click to Show/Hide the Complete Species Lineage) | ||||
| Interactome | |||||
| Disease Specific Interactions between Host Protein and DME (HOSPPI) | |||||
|---|---|---|---|---|---|
| ICD Disease Classification 02 Neoplasms | |||||
| ICD-11: 2A00 Brain cancer | Click to Show/Hide the Full List of HOSPPI: 3 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Brain neuroblastoma | Significant hypomethylation | |||
| Interaction Name | DNMT-CYB5A interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypomethylation p-value: 3.95E-23; delta-beta: -4.12E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the CYB5A gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Microsomal cytochrome MCB5. As a result, the interaction between DNMT and CYB5A can significantly affect the drug-metabolizing process of Microsomal cytochrome MCB5. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Myxopapillary ependymoma | Moderate hypomethylation | |||
| Interaction Name | DNMT-CYB5A interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypomethylation p-value: 9.59E-07; delta-beta: -2.66E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hypo-methylate the CYB5A gene, which leads to a moderatly increased expression of the drug-metabolizing enzyme Microsomal cytochrome MCB5. As a result, the interaction between DNMT and CYB5A can moderatly affect the drug-metabolizing process of Microsomal cytochrome MCB5. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Cerebellar liponeurocytoma | Significant hypomethylation | |||
| Interaction Name | DNMT-CYB5A interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypomethylation p-value: 6.86E-05; delta-beta: -6.21E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the CYB5A gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Microsomal cytochrome MCB5. As a result, the interaction between DNMT and CYB5A can significantly affect the drug-metabolizing process of Microsomal cytochrome MCB5. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2C12 Liver cancer | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| Non-coding RNA regulation | |||||
| hsa-miR-223-3p | Liver cancer | Suppression | |||
| miRBase ID | |||||
| Interaction Name | hsa-miR-223-3p--CYB5A regulation | [1] | |||
| Studied Cell Lines | HepG2 cell line | ||||
| Description | hsa-miR-223-3p is reported to suppress CYB5A mRNA translation by binding to the 3' untranslated region (3'UTR) of CYB5A mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Microsomal cytochrome MCB5. | ||||
| ICD-11: 2C82 Prostate cancer | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Prostate cancer | Moderate hypomethylation | |||
| Interaction Name | DNMT-CYB5A interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypomethylation p-value: 2.75E-04; delta-beta: -2.55E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hypo-methylate the CYB5A gene, which leads to a moderatly increased expression of the drug-metabolizing enzyme Microsomal cytochrome MCB5. As a result, the interaction between DNMT and CYB5A can moderatly affect the drug-metabolizing process of Microsomal cytochrome MCB5. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2C90 Renal cell carcinoma | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Renal cell carcinoma | Moderate hypomethylation | |||
| Interaction Name | DNMT-CYB5A interaction | ||||
| The Methylation Level of Disease Section Compare with the Other Disease Section | Moderate hypomethylation p-value: 1.42E-05; delta-beta: -2.58E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hypo-methylate the CYB5A gene, which leads to a moderatly increased expression of the drug-metabolizing enzyme Microsomal cytochrome MCB5. As a result, the interaction between DNMT and CYB5A can moderatly affect the drug-metabolizing process of Microsomal cytochrome MCB5. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
DME methylation in tissue other than the diseased tissue of patients
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2F37 Endocrine gland cancer | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Pituitary adenoma | Moderate hypermethylation | |||
| Interaction Name | DNMT-CYB5A interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypermethylation p-value: 1.96E-09; delta-beta: 2.72E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hyper-methylate the CYB5A gene, which leads to a moderatly decreased expression of the drug-metabolizing enzyme Microsomal cytochrome MCB5. As a result, the interaction between DNMT and CYB5A can moderatly affect the drug-metabolizing process of Microsomal cytochrome MCB5. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD Disease Classification 12 Respiratory system diseases | |||||
| ICD-11: CA23 Asthma | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Asthma | Significant hypermethylation | |||
| Interaction Name | DNMT-CYB5A interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 2.91E-02; delta-beta: 3.85E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYB5A gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Microsomal cytochrome MCB5. As a result, the interaction between DNMT and CYB5A can significantly affect the drug-metabolizing process of Microsomal cytochrome MCB5. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| References | |||||
|---|---|---|---|---|---|
| 1 | Regulation of cytochrome b5 expression by miR-223 in human liver: effects on cytochrome P450 activities. Pharm Res. 2014 Mar;31(3):780-94. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.